Coherus Oncology develops and sells LOQTORZI, a cancer medicine, and is developing two other cancer treatment candidates in clinical studies. It last closed at $0.49 on Nov 17, down 3.38% on the day. The average 12-month price target from 2 analysts is $7.50 (+1434.4% from the last close), with a high of $8.00 and a low of $7.00.
Only 2 firms rated CHRS in the past 90 days, not enough for a consensus
Average 12-month target
$7.50
▲ 1434.4% upside
Based on 2 analysts who set a price target on CHRS in the past 90 days. The average target is $7.50, with a high of $8.00 and a low of $7.00, compared with the last close of $0.49.
Low $7.00Avg $7.50High $8.00
Blue marker: last close $0.49
Highest target$8.00
Average target$7.50
Lowest target$7.00
Latest rating changes
GuggenheimTarget lowered
Nov 10Buy$10 → $8
HC Wainwright & Co.Assumed coverage
Oct 29Buy$7
GuggenheimMaintained
Aug 7Buy$10
GuggenheimInitiated
May 11Buy$12
Date
Firm
Action
Rating
Price target
Nov 10
Guggenheim
Target lowered
Buy
$10 → $8
Oct 29
HC Wainwright & Co.
Assumed coverage
Buy
$7
Aug 7
Guggenheim
Maintained
Buy
$10
May 11
Guggenheim
Initiated
Buy
$12
Loading…
Technical Analysis
CHRS · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 64% below its 20 day and 109% below its 50 day average. It is 197% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the Pivot at $0.47, and the nearest resistance the Pivot R1 at $0.51.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.7%/day
Key levels
$2.6252 week high+434.7%
$1.45200 day average+195.9%
$1.21100 day average+146.9%
$1.09Swing high (Oct 15)+122.4%
$1.0250 day average+108.2%
$0.8020 day average+63.3%
$0.51Pivot R1+4.1%
$0.49Last close
$0.47Pivot−4.1%
$0.45Pivot S1−8.2%
$0.4352 week low−12.2%
Indicators
RSI (14)
27.12
Oversold below 30
Oversold
MACD
-0.15
Below its signal line
Bearish
Stochastic
4.8
Near the bottom of its range
Oversold
ADX (14)
33.6
Trending down
Williams %R
-92.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-135.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−39.3%
Change over 10 sessions
Bearish
ATR (14)
$0.09
Typical daily range, 17.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 43.2%/day
Key levels
$2.6252 week high+434.7%
$1.45200 day average+195.9%
$1.21100 day average+146.9%
$1.09Swing high (Oct 15)+122.4%
$1.0250 day average+108.2%
$0.8020 day average+63.3%
$0.51Pivot R1+4.1%
$0.49Last close
$0.47Pivot−4.1%
$0.45Pivot S1−8.2%
$0.4352 week low−12.2%
Indicators
RSI (14)
23.00
Oversold below 30
Oversold
MACD
-0.23
Below its signal line
Bearish
Stochastic
4.1
Near the bottom of its range
Oversold
ADX (14)
27.0
Trending down
Williams %R
-94.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-199.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−63.3%
Change over 10 sessions
Bearish
ATR (14)
$0.21
Typical daily range, 43.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CHRS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CHRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CHRS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CHRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CHRS is in one of them and how their past CHRS trades turned out.
Coherus Oncology is a cancer drug company based in Redwood City, California. Its main product is LOQTORZI, an antibody medicine that blocks the PD-1 pathway. It is approved in the United States for nasopharyngeal carcinoma, a cancer of the upper throat, and the company sells it for treating cancer patients. The company is also developing two other cancer treatment candidates in clinical studies, aimed at cancers such as liver, head and neck, and colorectal cancer.